Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. - Luo N; Formisano L; Gonzalez-Ericsson PI; Sanchez V; Dean PT; Opalenik SR; Sanders ME; Cook RS; Arteaga CL; Johnson DB; Balko JM (Oncoimmunology, 2018)